CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Autores: Yau, T.; Park, J. W.; Finn, R. S.; Cheng, A. L. ; Mathurin, P.; Edeline, J.; Kudo, M.; Han, K. H. ; Harding, J. J. ; Merle, P. ; Rosmorduc, O. ; Wyrwicz, L. ; Schott, E.; Choo, S. P. ; Kelley, R. K. ; Begic, D. ; Chen, G. ; Neely, J.; Anderson, J. ; Sangro Gómez-Acebo, Bruno Carlos